Lates News

According to AI Quick News, Minsheng Securities released a research report on August 6 recommending a buy rating for Jiuzhou Pharmaceuticals (603456.SH). The rating reasons mainly include: 1) Income structure breakdown: steady growth in CDMO business, while specialty APIs saw a slight decline year-on-year; 2) CDMO funnels data update: the scale of project funnels continues to expand, and the number of commercial projects is steadily increasing; 3) Significant effectiveness in building emerging technology platforms, with rapid growth in overseas orders for TIDES business. (Daily Economic News)